Lycotec has developed and a new liver-targeting delivery technology for orally administered drugs, vitamins, and other bioactive molecules.
This technology could benefit those drugs which particular targeting liver specific biochemical pathways, for example statins.
Results of the proof of concept pharmaco-dynamic clinical trial, for our proprietary formulation LycoStatinTM, containing 20 mg of Simvastatin are presented on the figure below.
Lycotec technology promotes selective delivery of drug molecules to the liver, and consequently reduces their presence, and hence side-effects, in extra-hepatic tissues.
The technology can be applied for other small molecules as well as for peptides and some proteins.
For licensing opportunities, please contact us